See more : Socionext Inc. (6526.T) Income Statement Analysis – Financial Results
Complete financial analysis of Wakamoto Pharmaceutical Co.,Ltd. (4512.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Wakamoto Pharmaceutical Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Iovance Biotherapeutics, Inc. (0JDK.L) Income Statement Analysis – Financial Results
- American Financial Group, Inc. (AFGE) Income Statement Analysis – Financial Results
- Growthpoint Properties Australia (GOZ.AX) Income Statement Analysis – Financial Results
- Firm Capital Mortgage Investment Corporation (FCMGF) Income Statement Analysis – Financial Results
- EMCO Limited (EMCO.NS) Income Statement Analysis – Financial Results
Wakamoto Pharmaceutical Co.,Ltd. (4512.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.wakamoto-pharm.co.jp
About Wakamoto Pharmaceutical Co.,Ltd.
Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.74B | 8.66B | 8.38B | 8.89B | 10.92B | 10.74B | 10.90B | 10.83B | 11.19B | 10.61B | 10.31B | 9.92B | 9.43B | 9.67B | 9.78B | 10.08B | 10.18B |
| Cost of Revenue | 4.20B | 4.55B | 4.03B | 4.41B | 4.72B | 4.62B | 4.82B | 4.97B | 4.92B | 4.78B | 4.71B | 4.62B | 4.35B | 4.49B | 4.10B | 3.85B | 3.55B |
| Gross Profit | 3.54B | 4.11B | 4.36B | 4.49B | 6.19B | 6.12B | 6.08B | 5.86B | 6.28B | 5.84B | 5.60B | 5.31B | 5.08B | 5.18B | 5.68B | 6.23B | 6.63B |
| Gross Profit Ratio | 45.76% | 47.44% | 51.96% | 50.45% | 56.73% | 56.96% | 55.82% | 54.08% | 56.08% | 55.01% | 54.33% | 53.47% | 53.89% | 53.53% | 58.11% | 61.78% | 65.16% |
| Research & Development | 513.31M | 580.45M | 593.96M | 641.51M | 1.73B | 1.61B | 1.38B | 1.14B | 1.30B | 0.00 | 0.00 | 0.00 | 792.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.16B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.22B | 3.33B | 3.78B | 4.54B | 5.40B | 4.83B | 6.16B | 4.56B | 4.82B | 0.00 | 0.00 | 0.00 | 4.74M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 15.66M | 46.37M | 104.70M | 47.13M | -14.71M | -45.39M | 24.58M | 49.80M | 97.29M | 273.24M | 198.62M | 283.88M | 213.31M | 221.22M | 385.64M | 270.88M |
| Operating Expenses | 3.74B | 3.97B | 4.37B | 5.24B | 7.19B | 6.51B | 6.16B | 5.77B | 6.19B | 5.74B | 5.48B | 5.29B | 5.58B | 5.93B | 5.73B | 6.02B | 6.03B |
| Cost & Expenses | 7.93B | 8.52B | 8.40B | 9.65B | 11.91B | 11.13B | 10.97B | 10.75B | 11.11B | 10.51B | 10.19B | 9.90B | 9.93B | 10.43B | 9.82B | 9.88B | 9.57B |
| Interest Income | 29.00K | 28.00K | 25.00K | 22.00K | 25.00K | 33.00K | 30.00K | 33.00K | 569.00K | 752.00K | 737.00K | 641.00K | 625.00K | 1.30M | 3.04M | 18.21M | 12.07M |
| Interest Expense | 531.00K | 578.00K | 575.00K | 569.00K | 669.00K | 1.67M | 3.16M | 5.62M | 9.54M | 14.61M | 23.32M | 27.30M | 28.93M | 27.97M | 19.05M | 0.00 | 0.00 |
| Depreciation & Amortization | 345.46M | 363.65M | 470.08M | 484.31M | 468.19M | 471.22M | 527.05M | 676.04M | 746.45M | 766.99M | 706.93M | 787.47M | 1.01B | 1.20B | 720.10M | 553.41M | 512.27M |
| EBITDA | 504.84M | 575.81M | 755.52M | -218.12M | -442.18M | 243.09M | 704.38M | 851.65M | 884.47M | 1.02B | 2.09B | 1.26B | 909.71M | 605.72M | 880.14M | 1.16B | 1.12B |
| EBITDA Ratio | 6.52% | 7.50% | 6.54% | -1.35% | -4.01% | 0.98% | 4.16% | 7.09% | 7.87% | 9.57% | 10.73% | 10.16% | 8.42% | 6.86% | 9.21% | 7.51% | 12.71% |
| Operating Income | -195.51M | 141.47M | -13.39M | -754.95M | -996.28M | -391.02M | -73.49M | 87.34M | 83.22M | 102.80M | 125.92M | 21.21M | -499.13M | -755.38M | -43.89M | 203.52M | 608.25M |
| Operating Income Ratio | -2.53% | 1.63% | -0.16% | -8.49% | -9.13% | -3.64% | -0.67% | 0.81% | 0.74% | 0.97% | 1.22% | 0.21% | -5.29% | -7.81% | -0.45% | 2.02% | 5.97% |
| Total Other Income/Expenses | 354.37M | 70.11M | 298.24M | 51.94M | 85.24M | 161.22M | 247.66M | 82.65M | 42.82M | 28.87M | 1.20B | 427.38M | 371.64M | 128.56M | 184.88M | 403.85M | 109.01M |
| Income Before Tax | 158.85M | 211.57M | 284.86M | -703.01M | -911.04M | -229.80M | 174.17M | 169.99M | 126.05M | 231.67M | 1.36B | 448.59M | -127.49M | -626.82M | 141.00M | 607.37M | 717.26M |
| Income Before Tax Ratio | 2.05% | 2.44% | 3.40% | -7.90% | -8.34% | -2.14% | 1.60% | 1.57% | 1.13% | 2.18% | 13.17% | 4.52% | -1.35% | -6.48% | 1.44% | 6.02% | 7.04% |
| Income Tax Expense | 49.90M | 73.32M | 46.31M | -101.15M | 745.50M | -48.52M | 48.21M | 75.24M | 105.53M | 148.32M | 513.98M | 265.25M | 94.68M | -201.32M | 92.48M | 256.01M | 310.37M |
| Net Income | 108.96M | 138.26M | 238.54M | -601.86M | -1.66B | -181.28M | 125.96M | 94.75M | 20.51M | 83.34M | 844.79M | 183.34M | -222.17M | -425.51M | 48.52M | 351.36M | 406.89M |
| Net Income Ratio | 1.41% | 1.60% | 2.85% | -6.77% | -15.17% | -1.69% | 1.16% | 0.87% | 0.18% | 0.79% | 8.19% | 1.85% | -2.36% | -4.40% | 0.50% | 3.49% | 4.00% |
| EPS | 3.14 | 3.98 | 6.87 | -17.34 | -47.73 | -5.22 | 3.63 | 2.73 | 0.59 | 2.40 | 24.30 | 5.27 | -6.38 | -12.30 | 1.41 | 10.20 | 12.00 |
| EPS Diluted | 3.14 | 3.98 | 6.87 | -17.34 | -47.73 | -5.22 | 3.63 | 2.73 | 0.59 | 2.40 | 24.30 | 5.27 | -6.38 | -12.30 | 1.41 | 10.20 | 12.00 |
| Weighted Avg Shares Out | 34.71M | 34.71M | 34.71M | 34.71M | 34.71M | 34.71M | 34.71M | 34.73M | 34.74M | 34.75M | 34.77M | 34.79M | 34.80M | 34.60M | 34.41M | 34.45M | 33.90M |
| Weighted Avg Shares Out (Dil) | 34.71M | 34.71M | 34.71M | 34.71M | 34.71M | 34.71M | 34.71M | 34.73M | 34.74M | 34.75M | 34.77M | 34.79M | 34.80M | 34.60M | 34.41M | 34.45M | 33.90M |
Source: https://incomestatements.info
Category: Stock Reports